847591-62-2

Basic information

• Product Name: ICG-001
• Synonyms: ICG-001;ICG-1;(6S,9aS)-Hexahydro-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide;2H-Pyrazino[1,2-a]pyriMidine-1(6H)-carboxaMide, hexahydro-6-[(4-hydroxyphenyl)Methyl]-8-(1-naphthalenylMethyl)-4,7-dioxo-N-(phenylMethyl)-, (6S,9aS)-;ICG-001/ICG001;(6S,9aS)-Hexahydro-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide ICG001;ICG 001, >=98%;(6S,9AS)-6-(4-hydroxybenzyl)-N-benzyl-8-(naphthalen-1-ylmethyl)-4,7-dioxo-hexahydro-2H-pyrazin
• CAS NO: 847591-62-2
• Molecular Formula: C33H32N4O4
• Molecular Weight: 548.63158
• EINECS: -0
• Product Categories: Aromatics;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Inhibitors
• Mol File: 847591-62-2.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 895.6 °C at 760 mmHg
• Flash Point: 495.4 °C
• Appearance: /
• Density: 1.37
• Storage Temp.: +2C to +8C
• Solubility: Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 25 mg/ml).
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
• CAS DataBase Reference: ICG-001(CAS DataBase Reference)
• NIST Chemistry Reference: ICG-001(847591-62-2)
• EPA Substance Registry System: ICG-001(847591-62-2)

Safety Data

• Hazardous Substances Data: 847591-62-2(Hazardous Substances Data)

Usage

Description

ICG-001 is a β-turn peptidomimetic molecule inhibitor that specifically targets and blocks the interaction between β-catenin and CBP, thereby inhibiting TCF/β-catenin mediated transcription.

Uses

Used in Pharmaceutical Industry:
ICG-001 is used as a therapeutic agent for the treatment of various diseases, including cancer, by inhibiting the β-catenin-Tcf-mediated transcription pathway, which plays a crucial role in cell proliferation, differentiation, and tumorigenesis.
Used in Cancer Research:
ICG-001 is used as a research tool in cancer biology to study the role of the Wnt/β-catenin signaling pathway in tumor development and progression. By inhibiting the β-catenin/CBP interaction, ICG-001 helps researchers understand the molecular mechanisms underlying cancer growth and identify potential therapeutic targets.
Used in Drug Development:
ICG-001 serves as a lead compound in the development of novel drugs targeting the Wnt/β-catenin signaling pathway. Its ability to inhibit the β-catenin-Tcf-mediated transcription makes it a promising candidate for the treatment of various cancers and other diseases associated with the dysregulation of this pathway.

Biochem/physiol Actions

Cell permeable: yes

References

1) Emami?et al.?(2004),?A small molecule inhibitor of β-catenin/CREB-binding protein transcription;? Proc. Natl. Acad. Sci. USA,?101?12682 2) Zhou?et al.?(2012), Interactions?between β-catenin and transforming growth factor-β signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcription co-activator cAMP-response element-binding protein (CERB)-binding protein (CBP);??J. Biol. Chem.,?287?7026

Upstream product

• 952110-63-3 2,2-diethoxy-N-(naphthalen-1-ylmethyl)ethan-1-amine 
• 66-77-3 1-naphthaldehyde 

Relevant articles and documents

SYNTHESIS AND ANALYSIS OF NOVEL COMPOUND CAPABLE OF INDUCING DIFFERENTIATION OF HUMAN MESENCHYMAL STEM CELL INTO HEPATOCYTE

The purpose is to select low-molecular-weight compounds which are effective in inducing differentiation of mesenchymal stem cell into hepatocyte and to develop a safe differentiation-inducing method having excellent efficiency of differentiating mesenchym